# Harmony Biosciences Reports Record Q2 2026 WAKIX Revenue of $261M, Reiterates $1B Full-Year Guidance

> news · REPORTED · 2026-08-15

Harmony Biosciences reported record Q2 2026 net revenue for WAKIX of $261.3 million, up 30% year-over-year, and reiterated full-year 2026 revenue guidance of $1.0 to $1.04 billion. The company also released initial Phase 1 data for its orexin-2 agonist BP-205 and announced FDA acceptance of the Pitolisant GR NDA with an April 1, 2027 PDUFA date.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological disorders, including narcolepsy and related sleep disorders, anchored by its WAKIX pitolisant franchise.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.